RNS Number : 0121P
Genedrive PLC
16 June 2022

genedrive plc
("genedrive" or the "Company")

NICE to evaluate the Genedrive® MT-RNR1 Test under their Diagnostics Assessment Programme

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK's National Institute for Health and Clinical Excellence ('NICE') has started an evaluation of the Genedrive® MT-RNR1 test via their Diagnostics Assessment Programme ('DAP'). DAP evaluations are designed to provide robust recommendations on the use of new products, which is presented in the form of NICE guidance, and to promote rapid and consistent adoption of clinically innovative and cost-effective diagnostic technologies in the NHS.

An independent advisory committee considers the evidence provided, makes draft recommendations for public consultation and ultimately makes final recommendations for publication in NICE guidance. The guidance produced is used by NHS commissioners, practitioners, healthcare operational managers and purchasing and procurement organisations.

genedrive's assay is the world's first rapid point of care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given certain antibiotics. Those that carry the variant can then be given alternative treatments following detection of the variant by the Genedrive® MT-RNR1 test.

David Budd, CEO of genedrive plc, said: *"We are grateful to NICE for their engagement and interest in our innovative technology and pleased that the Genedrive® MT-RNR1 test was selected for this programme following successful publication of* the NICE Medtech innovation briefing ("MIB290") in March*. The NICE guidance is an important element required to drive uptake and adoption of the test in the NHS by demonstrating the cost-saving efficiencies. The application of Genedrive's technology shows how a rapid, affordable, point-of-care test could impact patients' treatment and quality of life."*

For further details please contact:

genedrive plc David Budd: CEO / Russ Shaw: CFO	+44 (0)161 989 0245
Peel Hunt LLP (Nominated Adviser and Joint Broker) James Steel	+44 (0)20 7418 8900
finnCap (Joint Broker) Geoff Nash / Kate Bannatyne / Alice Lane	+44 (0)20 7220 0500

Walbrook PR Ltd (Media & Investor Relations)
Paul McManus / Anna Dunphy

+44 (0)20 7933 8780 or
genedrive@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876 741 001

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of MT-RNR1, HCV, certain military biological targets, and a high throughput SARS-CoV-2 assay. The Company recently released a point of care test for Covid-19.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPUBUQUPPGWA